Intec Pharma offers a unique solution to the pharmaceutical industry with its proprietary CR gastric-retentive drug delivery platform. Specifically, Intec is positioned to penetrate two important market segments: drugs with a narrow absorption window and drugs for local treatment of gastrointestinal conditions such as GERD, obesity and IBS. Additional markets include drug delivery of macromolecules and peptides.
Despite advances made in drug delivery technologies, current oral drug administration methods have only limited use for a variety of important drugs with distinct absorption characteristics. A "narrow absorption window" characterizes drugs that are selectively absorbed by specific carriers that exist only in the upper part of the small intestine. These specific carriers do not exist in the lower parts of the intestine. Drugs that pass this narrow absorption window will not be successfully absorbed, thereby undermining their functionality. In addition, because excessive doses are administered to compensate for the narrow absorption window, patients who must take these oral compounds suffer from a plethora of adverse side effects.

•  Are absorbed mainly in the upper GI region
•  Are absorbed through transport mechanisms
•  Act locally in the GI tract
•  Are associated with significant ADR due to fluctuations in plasma levels
•  Are associated with ADR due to exposure in the distal GI region
•  Possess a unique pharmacokinetic profile

•  Amino Acid Analogs (e.g., various drugs for CNS disorders)
•  Small Peptide Peptidomimetics (e.g. cardiovascular drugs)
•  Beta-lactams and Cephalosporins (antibiotics)
•  Nucleoside Analogs (e.g., various anti viral drugs)
•  Local gastrointestinal therapeutics (e.g., drugs for GI infections, obesity, IBS, IBD)
•  Drugs that are not administered orally (e.g., peptide based drugs)